FDA ONP Leadership On Switches Could Benefit Chronic Therapies
This article was originally published in The Tan Sheet
Executive Summary
The recent elevation of FDA's OTC drug division to office status sets the stage for the unit to take a more prominent role in evaluating Rx-to-OTC switches for chronic conditions